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ummary  Sinusoidal  obstruction  syndrome  (SOS)  is  characterized  by  damage  to  small  hepatic
essels affecting  particularly  sinusoidal  endothelium.  Damaged  sinusoids  can  be  associated
ith a  partial  or  complete  occlusion  of  small  hepatic  veins,  hence  the  previous  denomina-
ion of  hepatic  veno-occlusive  disease  (VOD).  Exposure  to  certain  exogenous  toxins  appears  to
e speciﬁc  to  this  condition  and  is  frequently  included  in  its  deﬁnition.  Typical  histopathological
eatures  of  SOS  in  a  liver  biopsy  specimen  are  presented  in  the  text.  The  purpose  of  this  article
s to  provide  an  overview  on  the  different  entities  corresponding  to  this  general  deﬁnition.  Such
ntities include:  (i)  liver  disease  related  to  pyrrolizidine  alcaloids;  (ii)  liver  injury  related  to
onditioning  for  hematopoietic  stem  cell  transplantation;  (iii)  vascular  liver  disease  occurring
n patients  treated  with  chemotherapy  for  liver  metastasis  of  colorectal  cancer;  and  (iv)  other
iver diseases  related  to  toxic  agents.
 2016  Elsevier  Masson  SAS.  All  rights  reserved.
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river disease related to pyrrolizidine alcaloids
his  entity  was  ﬁrst  recognized  in  South  Africa  in  1920
s  cirrhosis  resulting  from  Senecio  poisoning  in  humans.  It
as  further  characterized  in  the  West  Indies  in  the  1950s,
ased  on  conspicuous  congestion  of  sinusoids  and  hemor-
hagic  necrosis  in  centrilobular  area  while  large  hepatic
eins  were  patent  and  there  was  a  nonthrombotic  occlusion
f  central  and  sublobular  hepatic  veins  by  subendothelial
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210-7401/© 2016 Elsevier Masson SAS. All rights reserved.dema  and  ﬁbrosis  [1]. It  was  soon  recognized  that  the  dis-
ase  was  associated  to  the  consumption  of  ‘‘bush  tea’’.
 relationship  with  a  similar  lesions  encountered  in  cat-
le  exposed  to  pyrrolizidine  alkaloid-containing  plants  was
apidly  established.  Several  variants  of  clinical  presentation
ere  described,  including  an  acute  presentation  with  rapid
nd  massive  abdominal  swelling  and  pain  associated  with
emorrhagic  centrilobular  necrosis;  a  subacute  presentation
ith  recurrent  ascites,  splenomegaly  and  hepatomegaly,
ssociated  with  extensive  ﬁbrosis  in  centrilobular  areas;  and
 chronic  variant  indistinguishable  at  bedside  from  cirrhosis
f  other  origin,  but  showing  a  venocentric  type  of  cirrho-
is  at  histological  examination.  Young  children  and  adults
ere  both  affected.  A  possible  full  clinical,  biochemical  and
athological  recovery  was  recorded  in  half  the  patients,  a
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rapid  death  in  20%  of  patients,  and  the  development  of
decompensated  liver  disease  in  the  rest.  In  1970,  ultra-
structural  studies  on  liver  biopsy  specimens  from  6  children
revealed  the  extensive  ‘‘devastation’’  of  the  endothelium,
the  extravasation  of  erythrocytes  the  space  of  Disse,  and
massive  dropout  of  parenchymal  cells  [2].
Pyrrolizidine  alcaloids  are  many,  varying  in  structure  and
origin.  They  are  mostly  found  in  plants,  of  several  families,
including  about  3%  of  the  world’s  ﬂowering  plants.  Following
ingestion,  they  are  absorbed  from  the  gut  and  transformed
by  hepatic  cytochrome  P450,  CYP3A  and  CYP2B  into  so-
called  DHP  esters.  These  metabolites  react  rapidly  with
functional  groups  on  DNA,  proteins  or  glutathione  to  form
DHP  adducts.  Rapid  spontaneous  hydrolysis  of  DHP  esters
form  less  reactive  intermediates  that  can  diffuse  outside  the
liver.  DHP  adducts  may  further  induce  toxic  effects.  Inter-
species  differences  in  metabolism  to  toxic  intermediates
likely  explain  part  of  the  differences  in  species  susceptibility
to  pyrrolizidine  alcaloids  [3].
In  the  1970s,  besides  the  endemic  cases  related  to  con-
sumption  of  bush  teas,  epidemic  forms  of  the  disease  have
been  described  as  a  result  of  consuming  products  made  from
wheat  contaminated  with  seeds  of  pyrrolizidine  alkaloid-
containing  plants  [4].  These  epidemics  occurred  in  a  context
of  war  or  drought  modifying  normal  harvesting  and  allow-
ing  for  toxic  plants  to  contaminate  crops.  Attack  rates
have  been  up  to  30%  based  on  clinical  examination,  and
associated  to  fatalities  or  complete  recovery  within  the
same  epidemics.  Where  histopathological  studies  could  be
obtained,  ﬁndings  have  been  similar  to  those  from  endemic
cases,  spanning  from  acute  centrilobular  congestion  with
occlusion  of  central  veins  to  cirrhosis.  Such  outbreaks  of
VOD/SOS  have  still  been  reported  into  the  1990s.
Since  the  mid-1980s,  a  number  of  sporadic  cases  related
to  the  consumption  of  herbal  remedies  have  been  reported
from  western  countries  or  China.  Attention  has  recently
been  drawn  to  the  possible  SOS/VOD  occurring  as  a  result  of
erroneous  substitution  of  pyrrolizidine  alkaloid-containing
to  non-pyrrolizidine  alkaloid  in  herbal  remedy  [5].  Recent
epidemiological  studies  have  focused  on  low-level  dietary
exposure  to  pyrrolizidine  alcaloids,  e.g.  consuming  honey
from  plants  containing  pyrrolizidine  alcaloids  [6].  Evidence
for  signiﬁcant  toxicity  from  such  low-level  dietary  exposure
is  still  lacking  but  difﬁcult  to  check  in  humans  [3]. They
could  explain  in  part  some  endemic/epidemic  toxic  liver
injury  related  to  co-exposure  to  DTT,  as  recently  reported
for  the  Hirmi  valley  disease  [7].  Recent  efforts  have  also
focused  on  identifying  accurate  biomarkers  for  exposure  to
pyrrolizidine  alkaloids.  Serum  pyrrole-protein  adducts  may
prove  valuable  in  this  regards  [5].
The  long  used  administration  of  pyrrolizidine  alkaloids  to
animals  of  various  species  has  allowed  a  demonstration  of  a
direct  responsibility  in  inducing  the  liver  changes.  A  repro-
ducible  rat  model  was  eventually  developed  consisting  of
gavage  with  monocrotaline  for  1  to  10  days  before  sacriﬁce
[8].  This  model  showed  early  injury  to  sinusoidal  and  central
vein  endothelium,  preceding  the  development  of  veno-
occlusive  lesions.  The  latter  could  actually  be  explained
by  the  contiguity  of  venous  subendothelial  areas  with  the
space  of  Disse,  where  endothelial  denudation  allowed  accu-
mulation  of  erythrocytes  and  cellular  or  non-cellular  debris.
These  ﬁndings  lead  the  new  denomination  of  ‘‘SOS’’  being
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roposed  for  the  entity,  in  order  to  better  account  for  dam-
ge  to  sinusoidal  endothelium  rather  than  occlusion  of  the
entral  vein  as  a  primary  event.  Coagulative  necrosis  of
epatocytes  was  also  found  to  occur  later  than  endothelial
njury  [8].  This  model  further  provided  clues  to  understand
ow  toxic  metabolites,  which  are  produced  in  the  hepa-
ocytes,  induce  more  severe  damage  to  endothelial  cells
han  hepatocytes.  Indeed,  decrease  in  glutathion  content
as  more  profound  in  endothelial  cells  than  in  hepatocytes.
oreover,  supply  in  exogenous  GSH  through  the  portal  vein
rotected  from  SOS/VOD  [9]. Further  experiments  showed
hat  the  earliest  changes  detectable  in  sinusoidal  endothe-
ium,  the  rounding  up  of  sinusoidal  endothelial  cell  was
ependent  on  the  production  of  matrix  metalloproteinase  9
nd  2  by  endothelial  cells  [10],  which  could  be  induced  by  a
ecreased  production  of  nitric  oxide  [11]. This  experimental
odel  also  allowed  for  showing  that  bone  marrow-derived
rogenitors  replace  sinusoidal  and  central  venous  endothe-
ial  cells  after  injury,  and  that  monocrotaline  suppresses
ndothelial  cell  progenitors  in  the  bone  marrow  and  circu-
ation  [12].  Thus,  SOS/VOD  appears  to  be  a  disease  resulting
rom  2  combined  mechanisms:
 toxic  injury  to  sinusoidal/central  venous  endothelial  cells;
 toxic  injury  to  bone  marrow  progenitors  preventing  the
replacement  of  the  injured  endothelial  cells  in  sinusoids
and  central  veins.
These  concepts  are  highly  relevant  to  hematopoietic
tem  cell  transplantation.
oxic liver injury related to conditioning for
ematopoietic stem cell transplantation
OS/VOD  was  ﬁrst  and  simultaneously  reported  by  sev-
ral  groups  in  1979—1980  as  a  fatal  complication  of
ematopoietic  stem  cell  transplantation  [13].  Because
hrombocytopenia  related  to  myeloablation  precluded  per-
utaneous  liver  biopsy  to  be  performed,  pathological  studies
ere  based  on  autopsy  material,  which  limits  the  interpre-
ation  of  the  data  because  ﬁndings  were  not  synchronous  to
linical  manifestations,  and  because  of  compounding  fac-
ors  contributing  to  death.  As  a result,  histopathological
eﬁnition  has  mostly  included  the  late  ﬁnding  of  ﬁbrous
bliteration  of  the  central  veins,  rather  than  the  ear-
ier  lesions  of  central  hemorrhagic  necrosis,  or  sinusoidal
hanges.  Still,  clinical  criteria  for  diagnosis  were  identiﬁed
n  the  basis  of  these  autopsy  data  [14].  Two  widely  used
linical  criteria  are  presented  in  Table  1.  The  accuracy  of
hese  criteria  is  limited  by  the  need  for  a  careful  exclusion  of
lternative  diagnoses,  particularly  viral  hepatitis,  bacterial
nfections,  graft  versus  host  disease,  and  other  drug  reac-
ions,  all  of  which  are  common  and  frequently  combined
n  the  setting  of  hepatopoietic  stem  cell  transplantation.
hen  clinical  diagnosis  was  compared  to  that  reached
hrough  transvenous  liver  biopsy,  a  high  rate  of  false  positive
iagnosis  of  SOS/VOD  was  found,  as  well  as  an  underestima-
ion  of  associated  conditions  [15,16].  Furthermore,  when
re-transplantation  and  post-transplantation  liver  biopsy
ould  be  compared  in  the  same  patient,  many  features
f  VOD  found  after  transplantation  were  already  present
380  
Table  1  Two  widely  used  sets  of  criteria  for  a  clinical  diag-
nosis of  veno-occlusive  disease.
Seattle  criteria  Baltimore  criteria
Within  20  days  of
transplantation,  two  of
three  ﬁndings  among  the
following
Within  30  days  of
transplantation,
bilirubinemia  >  34.2  mol/L
(2  mg/dL),  plus  2  other
ﬁndings  among  the
following
Bilirubin  >  34.2  mol/L
(2  mg/dL)
Hepatomegaly,  usually
painful
Hepatomegaly  or  RUQ
pain  of  liver  origin
>  5%  weight  gain
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ﬂuid  accumulation
Ascites
efore,  reﬂecting  the  importance  of  taking  into  account
re-transplant  condition  and  management  [17].  Seattle  and
altimore  criteria  yield  differing  estimates  for  the  incidence
f  SOS/VOD  [18,19].  Taken  together,  these  data  suggest
hat  the  widely  used  clinical  criteria  for  SOS/VOD  point
o  a  syndrome  of  liver  dysfunction  where  SOS/VOD  plays
 role  together  with  many  other  factors,  rather  than  to  a
iscrete  clinicopathological  entity.  A  hepatic  venous  pres-
ure  gradient  above  9  or  10  mmHg  appears  to  be  85—90%
peciﬁc  for  ﬁnding  SOS/VOD  lesions  at  liver  biopsy  [15,16].
bdominal  imaging  with  ultrasound,  CT  scan  or  magnetic
esonance  show  thickening  of  the  gallbladder,  enlarged  liver
nd  spleen,  ascites,  decreased  or  reversed  ﬂow  in  the  portal
ein,  all  of  which  being  non-speciﬁc  features  of  liver  disease
re  of  little  help  in  establishing  diagnosis  [20].
Depending  on  clinical  diagnostic  criteria  and  risk  factors,
he  incidence  of  SOS/VOD  has  ranged  between  0  and  50%
mong  transplantation  units,  and  the  fatality  rate  between
 and  45%  [14].  In  a  large  multicentric  prospective  survey,
he  incidence  was  5.3%  [21].  Major  risk  factors  for  the  occur-
ence  of  this  clinical  SOS/VOD  include:
 the  intensity  of  the  conditioning  regimen;
 the  autologous  or  allogeneic  type  of  hematopoietic  stem
cell  transplantation;
 exposure  to  estroprogestatives  in  women;
 second  myeloablative  transplantation;
 preexistent  liver  disease  (as  indicated  by  raised  serum
transaminase  activity)  [14].
High  intensity  regimens  include  those  using  both  busul-
an  and  cyclophosphamide,  or  cyclophosphamide  with  total
ody  irradiation  >  12  Gy,  or  cyclophosphamide  and  BCNU  and
toposide;  or  those  with  an  equivalent  intensity.  Based  on
x  vivo  studies,  cyclophosphamide  toxicity  to  sinusoidal
ndothelial  cells  appears  to  be  mediated  by  metabolism
o  toxic  intermediates  in  hepatocytes  and  to  depletion  in
lutathione  in  sinusoidal  endothelial  cells  [22].
In  the  multicentric  European  survey  mentioned  above,
OS/VOD  was  classiﬁed  as  mild  (i.e.  self-limited)  in  8%;  mod-
rate  (i.e.  with  complete  resolution  but  necessitating  ther-
py)  in  64%;  and  severe  (i.e.  leading  to  death  or  not  resolving
y  day  100)  in  28%  of  cases.  SOS/VOD  related  mortality
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as  1%  of  the  whole  series,  18%  of  SOS/VOD  patients,  and
7%  of  severe  SOS/VOD  [21]. Baseline  factors  predicting  the
ccurrence  of  severe  clinical  forms  have  not  been  well  char-
cterized.  In  patients  developing  SOS/VOD,  features  of  more
evere  liver  disease  (increased  serum  bilirubin  or  transami-
ase  levels,  increased  hepatic  venous  pressure  gradient)  are
ssociated  with  a  poorer  outcome  [14].
Prophylaxis  with  deﬁbrotide  has  been  recommended  in
hildren  at  high  risk  of  SOS/VOD.  Its  use  has  also  been  sug-
ested  in  such  adults  [23,24]. The  recommendation  is  based
n  a  positive  randomized  controlled  trial  in  356  children
25]. Actually,  22  (12%)  patients  receiving  deﬁbrotide  devel-
ped  clinically  deﬁned  SOS/VOD  by  day  30,  versus  35  (20%)  in
he  control  group  (P  = 0.05).  The  design  was  that  of  an  open-
abel  trial.  Non-relapse  mortality  was  9%  in  both  groups.
herefore,  the  clinical  impact  of  prophylactic  deﬁbrotide
dministration  appears  to  be  limited.  The  drug  however,
ppears  to  be  well  tolerated  [26]. Other  agents  proposed
or  prophylaxis  have  included  prostaglandin  E1,  pentoxy-
ylline,  heparin  and  antithrombin  but  none  of  these  are
ecommended  or  suggested  [23]. Ursodeoxycholic  acid  has
een  suggested  based  on  randomized  trials  showing  both
ecreased  and  unchanged  incidence  of  SOS/VOD,  but  with-
ut  any  impact  on  mortality  [23].
Data  on  treatment  for  established  SOS/VOD  from  ran-
omized  controlled  trials  are  lacking.  Most  studies  had  a
etrospective  design  or,  when  prospective,  used  histori-
al  controls.  Most  studies  reported  apparently  improved
utcomes.  Tolerance  appears  to  be  good.  As  a  result,  deﬁ-
rotide  has  been  recommended  for  treatment  of  SOS/VOD
espite  a  poor  methodological  quality  of  the  trials  [23].
issue  plasminogen  activator  is  not  recommended  as  sev-
ral  fatalities  related  to  the  use  of  this  agent  have  been
eported.  The  use  of  N-acetyl  cysteine  proved  inefﬁcient  in
 randomized  controlled  trial  [23].
Therefore,  the  most  effective  means  to  control  SOS/VOD
ssociated  to  hematopoietic  stem  cell  transplantation  has
een  to  reduce  the  exposure  to  chemotherapy  and  radio-
herapy,  including  conditioning  for  transplantation  and
rior  therapies  for  underlying  blood  disease.  Attempts  at
djusting  the  dose  of  myeloablative  agents  to  individual
olymorphism  in  drug  metabolism  has  thus  far  not  been
learly  associated  with  a  decreased  incidence  of  SOS/VOD
27].
In  summary,  SOS/VOD  related  to  hematopoietic  stem  cell
ransplantation  is  a  condition  decreasing  in  incidence  and
everity  due  to  increased  attention  to  a  reduced  exposure
o  toxic  chemotherapeutic  agents.  Unmet  needs  consist  of
ccurate  biomarkers  for  early  diagnosis  and  evaluation  of
atients  at  risk,  and  well-designed  therapeutic  trials  for
revention  and  management  of  the  disease.
inusoidal changes after chemotherapy for
iver metastasis
n  patients  with  liver  metastasis  from  colorectal  cancer,
reoperative  chemotherapy  is  widely  recommended,  based
n  a  well-established  association  with  improved  survival
28]. As  a  consequence,  an  abundance  of  liver  resection
pecimens  have  become  available  for  a comprehensive
valuation  of  the  changes  in  non-tumorous  areas.  Indeed,
Sinusoidal  obstruction  syndrome  381
Figure  1  Sinusoidal  obstruction  syndrome  related  to  oxaliplatin  use  for  colo-rectal  metastatic  liver  disease  (A:  fresh  cut  section  of
hepatectomy for  metastasis,  B:  Masson  trichrome,  C:  hematein  eosin-safran,  D:  argentation  stain):  Grossly,  diffuse  liver  congestion
has a  typical  nutmeg  aspect  corresponding  on  histology  to  extensive  veno-venous  dilatation  and  congestion  around  small  hepatic
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speciﬁc  sinusoidal  changes  resembling  those  of  SOS/VOD
have  been  described  of  such  patients  and  illustrated  in
Fig.  1.  They  consist  of  congestive  sinusoidal  dilatation  pre-
dominating  in  centrilobular  area  in  30—65%  of  patients,
perisinusoidal  ﬁbrosis  in  35—40%,  centrilobular  ﬁbrosis  in
30%,  atrophy  of  liver  cell  plate  but  few  necrotic  cells  bor-
dering  dilated  areas,  and  low-grade  nodular  regenerative
changes  in  12—20%  [29,30].  According  to  a  widely  used
classiﬁcation,  the  sinusoidal  lesions  are  mild  (less  than
1/3  of  the  lobule),  moderate  (1/3  to  2/3  of  the  lobule),
and  severe  (extending  in  the  whole  lobule)  in  about  30%
of  patients  each.  Only  in  occasional  patients  with  severe
lesions  was  extravasation  of  erythrocytes  in  the  space  of
Disse  described  [31,32].  Similar  lesions  were  not  found  in
control  patients  receiving  resection  without  preoperative
chemotherapy  [31].
There  is  a  clear  association  with  oxaliplatin-based
chemotherapy,  where  the  incidence  of  such  sinusoidal
changes  is  up  to  75%.  Still,  irinotecan-based  chemotherapy  is
also  associated  with  a  25—40%  incidence  of  similar  sinusoidal
changes  [29,30].  Actually  5-ﬂuorouracile  also  was  found
to  be  independently  associated  with  the  development  of
sinusoidal  changes  [33].  Co-administration  of  bevacizumab
has  been  shown  to  reduce  the  incidence  and  severity  of
sinusoidal  changes  [32—35].  A  murine  model  of  FOLFOX-
associated  sinusoidal  alterations  has  been  established  [36].
r
w
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cnd  a  sinusoidal  ﬁbrosis  is  frequently  observed  without  venous
n  this  model,  however,  sinusoidal  dilatation  and  hepato-
yte  atrophy  are  marked  but  endothelial  destruction  and
epatocyte  necrosis  are  inconspicuous.  There  is  evidence
or  an  activation  of  VEGF  and  IL6  pathway  mediators  both
n  patients  and  in  experimental  models  [36—38]. There  is
lso  evidence  that  changes  induced  in  the  tumor  itself  by
hemotherapeutic  agents  participate  in  inducing  sinusoidal
hanges  through  an  activation  of  pro-inﬂammatory  pathways
39]. Therefore,  it  is  still  unclear  whether  the  sinusoidal
hanges  observed  in  oxaliplatin  based  chemotherapy  are
dentical  to  SOS/VOD  observed  after  hematopoietic  stem
ell  transplantation  or  pyrrolizidine  alkaloid  exposure,  or
re  mostly  related  to  pro-inﬂammatory  mechanisms  [40].
Clinical  manifestations  associated  with  sinusoidal
hanges  in  patients  with  liver  metastasis  from  colorectal
arcinoma  appear  to  be  mild  or  absent.  However,  patients
ith  clinically  conspicuous  toxicity  from  chemotherapy
ould  have  been  denied  resection  and  thus  could  have
een  excluded  from  analyses  due  to  lack  of  histological
ata.  Actually,  reports  of  clinically  signiﬁcant  liver  injury
n  unoperated  or  operated  patients  are  scarce.  They  were
xclusively  observed  in  patients  receiving  intrahepatic  arte-
ial  administration  of  high  doses  of  oxaliplatin  combined
ith  systemic  or  hepatic  arterial  infusion  of  other  agents
41,42].  Therefore,  the  frequency  of  pathological  ﬁndings
ontrasts  with  the  rarity  of  the  clinical  manifestations.
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The  impact  of  sinusoidal  changes  associated  with
hemotherapy  on  the  outcome  of  patients  has  been  unclear.
ncreased  postoperative  morbidity  after  major  resection  has
een  reported  by  some  [43,44]  but  not  all  [30]  investiga-
ors.  Interestingly,  the  occurrence  of  sinusoidal  changes  has
een  associated  with  a  decreased  tumor  response  [29,45].
owever,  there  is  currently  no  evidence  for  an  increased
ortality  in  patients  with  sinusoidal  changes  [29].
Determinants  for  the  development  of  sinusoidal  changes
fter  chemotherapy  for  colorectal  cancer  have  not  been
learly  identiﬁed  yet.  Genetic  polymorphism  in  drug  metab-
lizing  enzymes,  such  as  glutathione  S-transferase,  has  been
ncriminated  [46].  Several  features  have  been  reported
s  predictive  for  a  ﬁnding  of  severe  sinusoidal  changes
n  resected  livers,  including  APRI  score  [44,47], serum
yaluronic  acid  [47],  and  a  reticular  pattern  of  enhance-
ent  at  CT  or  MRI  abdominal  imaging  following  injection  of
ascular  contrast  media  [48,49].  Of  note,  particular  focal
esions  simulating  metastasis  can  be  attributed  to  sinusoidal
hanges.  A  distinctive  feature  of  such  focal  lesions  is  their
ll-deﬁned  margin  on  hepatobiliary  phase  of  gadoxetic  acid
nhanced  and  diffusion  weighed  MR  imaging  [49].
In  summary,  oxaliplatin-associated  sinusoidal  lesions
s  a  pathological  entity  with  minimal  clinical  expression,
hich  is  not  entirely  speciﬁc  for  oxaliplatin  in  the  context
f  chemotherapy  for  liver  metastasis  of  colorectal  cancer.
he  impact  on  patients’  outcome  is  uncertain  or  minimal.
•
igure  2  Acute  sinusoidal  obstruction  syndrome  related  to  gemtuz
ation (A  &  B:  Masson  trichrome,  C:  hematein  eosin-safran;  D:  argen
o centrilobular  zones  around  the  terminal  hepatic  vein  *;  endothel
ematic deposition  in  Disse  space  and  to  hepatocyte  necrosis  aroundD.-C.  Valla,  D.  Cazals-Hatem
imilarity  with  pyrrolizidine  alkaloid  or  hematopoietic  stem
ell  transplantation  is  only  partial,  probably  related  to  the
se  of  clinically  less  toxic  doses  in  most  protocols  than
hose  used  for  preparation  to  hematopoietic  stem  cell
ransplantation.
inusoidal changes related to other drugs  or
onditions
able  2  presents  the  agents  which  have  been  reported  to  be
ssociated  with  SOS/VOD.  All  of  these  agents  share  causing
one  marrow  suppression  in  addition  to  SOS/VOD.
The  relationship  of  azathioprine  to  SOS/VOD  is  particu-
arly  unclear  for  several  reasons:
 there  is  no  animal  model;
 dose  relationship  is  not  obvious;
 similar  to  oxaliplatin,  lesions  have  been  described  under
various  denomination  including  SOS/VOD  but  also  peliosis,
sinusoidal  dilatation  and  nodular  regenerative  hyperpla-
sia; conditions  for  which  azathioprine  was  administered  have
been  reported  to  be  associated  with  sinusoidal  changes
including  Crohn’s  disease  [40],  renal  transplantation  and
liver  transplantation  [50,51].
umab  use  (Mylotarg)  after  haematopoietic  stem  cell  transplan-
tation  stain):  dilatation  and  congestion  of  sinusoids  are  limited
ial  cells  of  veins  and  sinusoids  are  damaged,  leading  to  a  huge
 the  central  veins.
Sinusoidal  obstruction  syndrome  
Table  2  Drugs  reported  to  be  associated  with  SOS/VOD.
6-mercaptopurine
6-thioguanine
Actinomycin  D
Azathioprine
Busulfan
Cytosine  arabinoside
Cyclophosphamide
Dacarbazine
Gemtuzumab-ozogamicin
Melphalan
Oxaliplatin
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Recently,  an  inherited  condition  combining  VOD  and
immunodeﬁciency  (so-called  VODI)  associated  with  muta-
tions  in  Sp110  [52]  has  been  described.  The  mechanism
explaining  VOD  in  this  condition  remains  unknown.  One
among  the  possible  explanations  could  be  a  concurrent
opportunistic  viral  infection  affecting  the  endothelium  of
sinusoids  or  central  vein.
Gemtuzumab-ozogamycin  is  a  monoclonal  antibody  tar-
geting  CD34  on  the  surface  of  myeloid  cells  but  also
sinusoidal  endothelial  cells.  This  antibody  is  conjugated  with
a  potent  cytotoxic  agent.  According  to  a  recent  report  on  a
large  survey,  the  incidence  of  SOS/VOD  was  about  9%  when
this  agent  was  used  for  the  treatment  of  acute  myeloid
leukemia,  and  the  mortality  rate  related  to  SOS/VOD  was
2.7%  [53].  Histopathological  ﬁndings  in  such  a  patient  are
presented  in  Fig.  2.
In  summary,  drugs  which  are  simultaneously  toxic  for
hepatic  endothelia  and  hematopoietic  cells  appear  to  be  at
risk  of  inducing  SOS/VOD.  However,  conditions  character-
ized  by  a  dysregulated  immunity,  and  therefore  indications
for  immunosuppressive  agents  including  azathioprine  also
appear  to  be  risk  factors  for  sinusoidal  changes,  which
makes  the  relationship  with  immunosuppressive  agents  dif-
ﬁcult  to  establish.  It  can  be  suggested  that  the  combination
of  several  factors  is  relevant  to  the  pathogenesis  of  these
uncommon  lesions:  an  immune-related  injury  and  a  drug
induced  injury.
Conclusions
Sinusoidal  changes  induced  by  pyrrolizidine  alkaloids  and
myeloablative  agents  are  likely  the  results  of  a  combination
of:  i)  a  direct,  dose-related  toxicity  to  sinusoidal  and  central
venous  endothelial  cell,  and  ii)  the  effect  of  chemotherapy
on  bone  marrow  progenitors  of  endothelial  cells  that  are
mobilized  for  the  repair  of  sinusoidal  lesions.  It  is  difﬁcult  to
ascertain  whether  the  associated  liver  cell  damage  is  a  pure
result  of  sinusoidal  injury,  or  a  result  of  combined  sinusoidal
injury  and  direct  toxicity  on  liver  cells.  There  is  evidence  for
a  generalized  alteration  of  endothelia  in  animal  models  of
pyrrolizidine  alkaloid  toxicity  but  also  in  recipients  of  HSCT,
when  they  develop  SOS/VOD  [54].  These  changes  include
features  of  endothelial  activation  and  apoptosis  [54].  Sinu-
soidal  changes  found  in  patients  receiving  chemotherapy
for  hepatic  metastasis  of  colorectal  adenocarcinoma  may
[383
esult  from  similar  mechanisms  despite  a  much  less  severe
linical  and  histological  expression,  or  may  stem  from  dif-
erent  pathways  implicating  proinﬂammatory  mediators.
ecreasing  the  intensity  of  chemotherapeutic  regimen  is
urrently  the  only  proven  means  to  prevent  or  decrease
he  severity  of  sinusoidal  changes  and  their  clinical  expres-
ion.  Long-term  effect  of  low  intensity  regimens  will  have
o  be  assessed.  Indeed,  portal  hypertension  due  to  nodu-
ar  regenerative  hyperplasia  may  represent  a  more  common
equela  of  infraclinical  sinusoidal  damage  than  currently
ecognized  [55].  Elucidation  of  the  mechanisms  under-
ying  the  recently  reported  SP110  mutations  associated
amilial  SOS/VOD  occurring  in  the  absence  of  exposure  to
hemotherapy  or  related  agents  [52]  will  shed  light  on  the
echanisms  involved  when  such  agents.
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